Teo, K., Gemmell, L., Mukherjee, R., Traynor, P. and Edwards, J. (2007) Bad expression influences time to androgen escape in prostate cancer. BJU International, 100(3), pp. 691-696. (doi: 10.1111/j.1464-410X.2007.07001.x)
Text
7752.pdf 111kB |
Publisher's URL: http://dx.doi.org/10.1111/j.1464-410X.2007.07001.x
Abstract
<b>OBJECTIVE</b>: To assess the role of selected downstream Bcl-2 family members (Bad, Bax, Bcl-2 and Bcl-xL) in the development of androgen-independent prostate cancer (AIPC), as androgen-deprivation therapy is the treatment of choice in advanced prostate cancer, yet patients generally relapse and progress to an AI state within 18–24 months. <b>PATIENTS, MATERIALS AND METHODS</b>: The patient cohort was established by retrospectively selecting patients with prostate cancer who had an initial response to androgen-deprivation therapy, but subsequently relapsed with AIPC. In all, 58 patients with prostate cancer were included with matched androgen-dependent (AD) and AI prostate tumours available for immunohistochemical analysis; two independent observers using a weighted-histoscore method scored the staining. Changes in Bad, Bax, Bcl-2 and Bcl-xL expression during transition to AIPC were evaluated and then correlated to known clinical variables. <b>RESULTS</b>: High Bad expression in AD tumours was associated with an increased time to biochemical relapse (<i>P</i> = 0.007) and a trend towards improved overall survival (<i>P</i> = 0.053). There were also trends towards a decrease in Bad (<i>P</i> = 0.068) and Bax (<i>P</i> = 0.055) expression with progression to AIPC. There were no significant results for Bcl-2 or Bcl-xL. <b>CONCLUSION</b>: There is evidence to suggest that Bad expression levels at diagnosis influence time to biochemical relapse and overall survival, and that levels of pro-apoptotic proteins Bad and Bax fall during AIPC development. Bad might therefore represent a possible positive prognostic marker and potential therapeutic target for AIPC in the future.
Item Type: | Articles |
---|---|
Additional Information: | The definitive version is available at www3.interscience.wiley.com |
Keywords: | Bad, Bax, Bcl-2, Bcl-xL, prostate cancer |
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Teo, Dr Katy and Edwards, Professor Joanne and McCall, Dr Pamela |
Authors: | Teo, K., Gemmell, L., Mukherjee, R., Traynor, P., and Edwards, J. |
Subjects: | R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | BJU International |
Publisher: | Wiley-Blackwell |
ISSN: | 1464-4096 |
ISSN (Online): | 1464-410X |
Published Online: | 02 June 2007 |
Copyright Holders: | Copyright © 2007 Wiley-Blackwell |
First Published: | First published in BJU International 100(3):691-696 |
Publisher Policy: | Reproduced in accordance with the copyright policy of the publisher. |
University Staff: Request a correction | Enlighten Editors: Update this record